Institute for Pathophysiology, University Hospital Essen, Hufelandstrasse 55, 45122 Essen, Germany.
Circ Res. 2011 Feb 4;108(3):314-23. doi: 10.1161/CIRCRESAHA.110.235028. Epub 2010 Dec 16.
The role of sphingosine-1-phosphate (S1P) and its receptors in the pathogenesis of atherosclerosis has not been investigated.
We hypothesized that the S1P receptor 3 (S1P(3)) plays a causal role in the pathogenesis of atherosclerosis.
We examined atherosclerotic lesion development in mice deficient for S1P(3) and apolipoprotein (Apo)E. Although S1P(3) deficiency did not affect lesion size after 25 or 45 weeks of normal chow diet, it resulted in a dramatic reduction of the monocyte/macrophage content in lesions of S1P(3)(-/-)/ApoE(-/-) double knockout mice. To search for putative defects in monocyte/macrophage recruitment, we examined macrophage-driven inflammation during thioglycollate-induced peritonitis. Elicited peritoneal macrophages were reduced in S1P(3)-deficient mice and expressed lower levels of tumor necrosis factor-α and monocyte chemoattractant protein-1. Bone marrow-derived S1P(3)-deficient macrophages produced less MCP-1 in response to lipopolysaccharide stimulation. In vitro, S1P was chemotactic for wild-type but not S1P(3)-deficient peritoneal macrophages. In vivo, S1P concentration increased rapidly in the peritoneal cavity after initiation of peritonitis. Treatment with the S1P analog FTY720 attenuated macrophage recruitment to the peritoneum. Studies in bone marrow chimeras showed that S1P(3) in both hematopoietic and nonhematopoietic cells contributed to monocyte/macrophage accumulation in atherosclerotic lesions. Finally, S1P(3) deficiency increased the smooth muscle cell content of atherosclerotic lesions and enhanced neointima formation after carotid ligation arguing for an antiproliferative/antimigratory role of S1P(3) in the arterial injury response.
Our data suggest that S1P(3) mediates the chemotactic effect of S1P in macrophages in vitro and in vivo and plays a causal role in atherosclerosis by promoting inflammatory monocyte/macrophage recruitment and altering smooth muscle cell behavior.
鞘氨醇-1-磷酸(S1P)及其受体在动脉粥样硬化发病机制中的作用尚未被研究。
我们假设 S1P 受体 3(S1P(3))在动脉粥样硬化发病机制中起因果作用。
我们检查了 S1P(3)缺陷和载脂蛋白(Apo)E 缺陷的小鼠的动脉粥样硬化病变发展。尽管 S1P(3)缺陷不影响正常饮食 25 或 45 周后的病变大小,但它导致 S1P(3)(-/-)/ApoE(-/-)双敲除小鼠的单核细胞/巨噬细胞含量显著减少。为了寻找单核细胞/巨噬细胞募集的潜在缺陷,我们研究了硫代乙醇酸盐诱导性腹膜炎期间的巨噬细胞驱动的炎症。在 S1P(3)缺陷的小鼠中,诱导的腹腔巨噬细胞减少,肿瘤坏死因子-α和单核细胞趋化蛋白-1 的表达水平降低。骨髓来源的 S1P(3)缺陷的巨噬细胞对脂多糖刺激的 MCP-1 产生较少。在体外,S1P 对野生型但不是 S1P(3)缺陷的腹腔巨噬细胞具有趋化性。在体内,腹膜炎开始后,S1P 浓度在腹腔中迅速增加。用 S1P 类似物 FTY720 治疗可减弱巨噬细胞向腹膜腔的募集。骨髓嵌合体研究表明,造血细胞和非造血细胞中的 S1P(3)都有助于动脉粥样硬化病变中单核细胞/巨噬细胞的积累。最后,S1P(3)缺陷增加了动脉粥样硬化病变中的平滑肌细胞含量,并增强了颈动脉结扎后的新生内膜形成,表明 S1P(3)在动脉损伤反应中具有抗增殖/抗迁移作用。
我们的数据表明,S1P(3)在体外和体内介导 S1P 对巨噬细胞的趋化作用,并通过促进炎症性单核细胞/巨噬细胞募集和改变平滑肌细胞行为在动脉粥样硬化中起因果作用。